

First-in-human Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults

NCT06984094

Status	RECRUITING
Phase	Phase 1
Sponsor	Clover Biopharmaceuticals AUS Pty
Enrollment	192 participants

Key Eligibility Criteria

Inclusion (4)

- Male and female participants 60 to 85 years of age at the screening visit.
- Individuals willing and able to comply with study requirements, including all scheduled visits, vaccination, laboratory tests, and other study procedures.
- Individuals willing and able to give an informed consent, prior to screening.
- Healthy participants as determined by medical history, physical examination, and clinical judgment of the investigator; participants with pre-existing stable medical conditions can be included.

Exclusion (4)

- Pregnancy or potential to become pregnant during the study.
- Acute disease or fever ($\geq 38^{\circ}\text{C}$) at time of vaccination.
- History of Guillain-Barré Syndrome (GBS).
- Recurrent or un-controlled neurological disorders or seizures.

Locations (1 total)

Fusion Clinical Research, Adelaide, Southern Australia, Australia